GlassScriptPhysician profile
Kelley Michel Bishop
NPI 1679596613
$2,490.14
in general payments reported to CMS, 2019-2025
16 companies · $503 in 2025
The $503 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,627 · 2023: $15.30 · 2024: $345 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $863.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $1,600.00 | 2022 | |
| Lilly USA, LLC | $277.95 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $139.97 | 2024-2025 | Wegovy, Saxenda, Ozempic |
| Pfizer INC. | $101.55 | 2024-2025 | |
| Abbvie INC. | $54.52 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $44.89 | 2024 | Voquezna |
| Astellas Pharma US INC | $40.11 | 2025 | Veozah |
| Shield Therapeutics INC | $37.80 | 2024 | |
| Amgen INC. | $36.11 | 2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $30.85 | 2024-2025 | Shingrix, Boostrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $30.05 | 2023-2024 | Farxiga |
| Global Blood Therapeutics, INC. | $26.65 | 2022 | |
| Esperion Therapeutics, INC. | $22.06 | 2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $18.02 | 2024 | Spravato |
| Merck Sharp & Dohme LLC | $15.01 | 2025 | Capvaxive, Gardasil 9 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $14.60 | 2024 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelley Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.